These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26666536)

  • 1. Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide.
    Liu AP; Lee V; Li CK; Ha SY; Chiang AK
    Ann Hematol; 2016 Feb; 95(3):501-7. PubMed ID: 26666536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
    Hijiya N; Thomson B; Isakoff MS; Silverman LB; Steinherz PG; Borowitz MJ; Kadota R; Cooper T; Shen V; Dahl G; Thottassery JV; Jeha S; Maloney K; Paul JA; Barry E; Carroll WL; Gaynon PS
    Blood; 2011 Dec; 118(23):6043-9. PubMed ID: 21967976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia.
    Locatelli F; Testi AM; Bernardo ME; Rizzari C; Bertaina A; Merli P; Pession A; Giraldi E; Parasole R; Barberi W; Zecca M
    Br J Haematol; 2009 Nov; 147(3):371-8. PubMed ID: 19747360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of clofarabine, etoposide, and cyclophosphamide shows limited efficacy as a bridge to transplant for children with refractory acute leukemia: results of a monitored prospective study.
    Toporski J; Król L; Dykes J; Håkansson Y; Pronk C; Turkiewicz D
    Pediatr Hematol Oncol; 2021 Apr; 38(3):216-226. PubMed ID: 33150834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.
    Hijiya N; Gaynon P; Barry E; Silverman L; Thomson B; Chu R; Cooper T; Kadota R; Rytting M; Steinherz P; Shen V; Jeha S; Abichandani R; Carroll WL
    Leukemia; 2009 Dec; 23(12):2259-64. PubMed ID: 19741725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD).
    Gossai N; Verneris MR; Karras NA; Gorman MF; Patel NJ; Burke MJ
    Bone Marrow Transplant; 2014 Mar; 49(3):440-2. PubMed ID: 24317126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
    Miano M; Pistorio A; Putti MC; Dufour C; Messina C; Barisone E; Ziino O; Parasole R; Luciani M; Lo Nigro L; De Rossi G; Varotto S; Bertorello N; Petruzziello F; Calvillo M; Micalizzi C
    Leuk Lymphoma; 2012 Sep; 53(9):1693-8. PubMed ID: 22303898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia.
    Messinger Y; Boklan J; Goldberg J; DuBois SG; Oesterheld J; Abla O; Martin A; Weinstein J; Hijiya N
    Pediatr Hematol Oncol; 2017 May; 34(4):187-198. PubMed ID: 29039989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clofarabine/cyclophosphamide for debulking before stem cell transplantation.
    Rabitsch W; Böhm A; Bojic M; Schellongowski P; Wöhrer S; Sliwa T; Keil F; Worel N; Greinix H; Hauswirth A; Kalhs P; Jaeger U; Valent P; Sperr WR
    Eur J Clin Invest; 2014 Aug; 44(8):775-83. PubMed ID: 24942362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group.
    Saito T; Hatta Y; Hayakawa F; Takahashi T; Hagihara M; Iida H; Minauchi K; Yamazaki E; Sugiura I; Murayama T; Sakura T; Mori N; Imai K; Yahagi Y; Atsuta Y; Saito AM; Hirakawa A; Kiyoi H; Matsumura I; Miyazaki Y;
    Int J Hematol; 2021 Mar; 113(3):395-403. PubMed ID: 33230647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Clofarabine Monotherapy or Combination Treatment in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia: A Pragmatic, Non-interventional Study in Korea.
    Choi JY; Hong CR; Hong KT; Kang HJ; Kim S; Lee JW; Jang PS; Chung NG; Cho B; Kim H; Koh KN; Im HJ; Seo JJ; Hahn SM; Han JW; Lyu CJ; Yang EJ; Lim YT; Yoo KH; Koo HH; Kook H; Jeon IS; Cho H; Shin HY
    Cancer Res Treat; 2021 Oct; 53(4):1184-1194. PubMed ID: 33421973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.
    Kebriaei P; Bassett R; Lyons G; Valdez B; Ledesma C; Rondon G; Oran B; Ciurea S; Alousi A; Popat U; Patel K; Ahmed S; Olson A; Bashir Q; Shah N; Jones R; Marin D; Rezvani K; Nieto Y; Khouri I; Qazilbash M; Hosing C; Shpall E; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):285-292. PubMed ID: 27816651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
    Steinherz PG; Shukla N; Kobos R; Steinherz L
    Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
    Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of clofarabine in Japanese patients with relapsed/refractory acute lymphoblastic leukaemia: a post-marketing surveillance study.
    Kazama H; Nishina S; Seto T
    Jpn J Clin Oncol; 2024 Jul; 54(7):778-786. PubMed ID: 38643356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
    Nelken B; Cave H; Leverger G; Galambrun C; Plat G; Schmitt C; Thomas C; Vérité C; Brethon B; Gandemer V; Bertrand Y; Baruchel A; Rohrlich P
    Pediatr Blood Cancer; 2016 Feb; 63(2):270-5. PubMed ID: 26376115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia.
    Tischer J; Stemmler HJ; Engel N; Hubmann M; Fritsch S; Prevalsek D; Schulz C; Zoellner AK; Bücklein V; Hill W; Ledderose G; Hausmann A
    Ann Hematol; 2013 Oct; 92(10):1379-88. PubMed ID: 23928857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.
    Jeha S; Razzouk B; Rytting M; Rheingold S; Albano E; Kadota R; Luchtman-Jones L; Bomgaars L; Gaynon P; Goldman S; Ritchey K; Arceci R; Altman A; Stine K; Steinherz L; Steinherz P
    J Clin Oncol; 2009 Sep; 27(26):4392-7. PubMed ID: 19652076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.
    Abd Elmoneim A; Gore L; Ricklis RM; Boklan J; Cooper T; Narendran A; Rolla K; Scott T; Arceci RJ
    Pediatr Blood Cancer; 2012 Dec; 59(7):1252-8. PubMed ID: 22887831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clofarabine-based combination chemotherapy for relapse and refractory childhood acute lymphoblastic leukemia].
    Arakawa Y; Koh K; Aoki T; Kubota Y; Oyama R; Mori M; Hayashi M; Hanada R
    Rinsho Ketsueki; 2014 Nov; 55(11):2316-9. PubMed ID: 25501414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.